Supplementary Table 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
Year: 2024
Type: supplementary-materials
Abstract: Supplementary Table 4. Impact of clinical, genomic features on time to treatment discontinuation for HER2 directed therapy in the FH-FMI CGDB.
Authors: Harshabad Singh, Pranshu Sahgal, Kevin Kapner, Steven M. Corsello, Hersh Gupta, Rahul Gujrathi, Yvonne Y. Li, Andrew D. Cherniack, Raquelle El Alam, Joseph Kerfoot, Elizabeth Andrews, Annette Lee, Chetan Nambiar, Alison M. Hannigan, Joshua Remland, Lauren Brais, Meghan E. Leahy, Douglas A. Rubinson, Benjamin L. Schlechter, Matthew Meyerson, Yanan Kuang, Cloud P. Paweletz, Jessica K. Lee, Julia C.F. Quintanilha, Andrew J. Aguirre, Kimberly J. Perez, Brandon M. Huffman, Humberto Rossi, Thomas A. Abrams, Sheheryar Kabraji, Livio Trusolino, Andrea Bertotti, Ewa T. Sicinska, Aparna R. Parikh, Brian M. Wolpin, Alexa B. Schrock, Marios Giannakis, Kimmie Ng, Jeffrey A. Meyerhardt, Jason L. Hornick, Nilay S. Sethi, James M. Cleary
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4394818474